Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

Use of Ketamine and Esketamine in the Pediatric Population: Current Evidence and Clinical Applications.

Thomas Kun Pak, Stephen Kimatian, Graham Emslie, Emine Rabia Ayvaci

Focus (American Psychiatric Publishing) April 1, 2026 DOI: 10.1176/appi.focus.20250040 (opens in new tab) via PubMed

Summary

AI-generated from the abstract

This review summarizes the pharmacodynamics, pharmacokinetics, adverse effects, contraindications, and clinical applications of ketamine and esketamine in adults and children. Ketamine, used clinically since the 1960s, is gaining recognition for treating chronic pain, refractory status epilepticus, major depressive disorder, and suicidality. Its bioavailability varies by route: intravenous 100%, intramuscular 64%-93% in adults and 41% in pediatric populations, intranasal 43%-48% in adults and 50% in pediatric populations, sublingual 29%-32%, rectal 25%-30%, epidural 77%, and oral 17%-18%, due to extensive first-pass hepatic metabolism. Dosing differences produce distinct clinical effects. Pediatric use is complicated by developmental stage, pharmacokinetics, and neurodevelopmental factors.

Study at a glance

Characteristics Review Peer reviewed
Population Adult and pediatric populations
Keywords Child/adolescent psychiatry Pharmacokinetics/pharmacodynamics
Key finding Ketamine and esketamine have diverse therapeutic applications, but their use in pediatric populations is complicated by developmental stage, pharmacokinetics, and neurodevelopmental factors.

Abstract

Ketamine is a well-established anesthetic agent that is gaining increasing recognition for its diverse therapeutic applications, including the management of chronic pain, refractory status epilepticus, major depressive disorder, and suicidality. Although it has been used clinically since the 1960s, multiple clinical trials with ketamine and esketamine in adults and pediatric populations are ongoing. There has been recent growing interest in ketamine and esketamine for psychiatric conditions in children and adolescents. The clinical use of ketamine is complex, in part because of the numerous available formulations and administration routes. Ketamine has different bioavailability depending on the route of administration: intravenous (100%), intramuscular (64%-93% in adults, 41% in pediatric populations), intranasal (43%-48% in adults, 50% in pediatric populations), sublingual (29%-32%), rectal (25%-30%), epidural (77%), and oral (17%-18%), which is due to extensive first-pass hepatic metabolism. Differences in dosing also produce distinct clinical effects. The challenges associated with ketamine use are further magnified in pediatric populations, for which developmental stage, pharmacokinetics, and neurodevelopmental factors play critical roles in guiding safe and effective treatment. In this review, the authors summarize the pharmacodynamics, pharmacokinetics, adverse effects and contraindications, and clinical applications of ketamine and esketamine among adult and pediatric populations.

Comments

No comments yet.

Log in to comment